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ABSTRACT
Esophageal carcinoma, squamous cell carcinoma, and adenocarcinoma, are a deadly 
serious malignancy. The delay in diagnosis due to the lack of specific symptoms in the 
early stages of the disease and the nature of esophageal cancer is very aggressive lead 
to a poor prognosis with a survival rate of small. Current management of esophageal 
cancer is recommended multimodal approach in the form of neoadjuvant chemotherapy 
or combined radiochemotherapy (CRT) and with surgery. In this article, multimodality 
treatment using chemotherapy and surgery on esophageal adenocarcinoma was reported. 
A 52-year-old male presented with a total obstruction of the esophagus and was planned 
to perform temporary gastrostomy for chemotherapy preparation. Gastrostomy found a 
solid and fixed tumor located in the gastroesophageal junction, with the size of 7 x 6 x 
5 cm3. He underwent a chemotherapy using the regimen of 8 cycles paclitaxel without 
radiotherapy due to the long queue of radiotherapy schedule. After chemotherapy, we re-
evaluated and planned to perform surgical removal of the tumor. During surgery, we found 
a total obstruction along with fibrosis of the esophagus but found no tumor/mass. We 
performed partial esophagectomy and end to side anastomosis using  anastomosis end to 
side using the CDH25 circular stapler. Surgery was carried out by the thoracoabdominal 
approach. The patient was discharged on day 12 in a stable condition and was undergoing 
soft diet. We planned to evaluate the patient using Carcinoembryonic Antigen (CEA) test 
and Positron Emission Tomography (PET) scan. In conclusion, multimodality treatment 
using chemotherapy and surgery on a case of one-third distal esophageal adenocarcinoma 
provides good results.
ABSTRAK
Karsinoma esofagus, baik karsinoma sel skuamosa, atau adenokarsinoma merupakan 
keganasan yang serius dan mematikan. Lambatnya diagnosis akibat kurangnya gejala 
spesifik pada stadium awal penyakit dan sifat kanker esofagus yang sangat agresif 
menyebabkan prognosis yang buruk dengan angka ketahanan hidup yang kecil. 
Penatalaksanaan terkini dari kanker esofagus yang direkomendasikan adalah pendekatan 
multimodalit berupa neoadjuvantchemotherapy atau combined radiochemotherapy (CRT) 
dan dengan pembedahan. Dalam makalah ini dilaporkan penatalaksanaan multimodalitas 
menggunakan kemoterapi dan pembedahan terhadap adenokarsinoma esophagus. 
Seorang laki-laki berusia 52 tahun dikonsulkan ke bagian bedah digesti dengan diagnosa 
obstuksi total esofagus dan di mintakan pembuatan gastrostomi temporer untuk persiapan 
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INTRODUCTION
Esophageal carcinoma and squamous cell 
carcinoma as well as adenocarcinoma are a 
serious malignancy with a poor prognosis and 
possibility of lethal in most cases. Esophageal 
carcinoma affects more than 450,000 people 
worldwide with a rapid incidence.1 Although 
the incidence is relatively rare when compared 
to other cancers, according to the National 
Cancer Institute, in 2012, in the United States 
about 35,781 patients with esophageal cancer 
were estimated and in 2015 about 16.980 
new cases with 15,590 deaths were reported.2  
Currently, esophageal cancer is the number 
6 leading cause of cancer death worldwide 
because its aggressivity and poor survival 
rate. Although it has been many developments 
in the diagnosis and management, the 5-year 
survival rate for patients diagnosed with 
esophageal cancer only range between 15% - 
20%.1,3
Esophageal cancer generally consists of 
two forms, squamous cell carcinoma, and 
adenocarcinoma.1 Squamous cell carcinoma 
is the most common histologic type (95%). 
The incidence of esophageal squamous cell 
carcinoma increases with age with a peak 
at the age of 70 years. The incidence of 
kemoterapi. Saat operasi gastrostomi teraba tumor keras di gastroesophageal junction, 
berukuran 7 x 6 x 5 cm3, padat terfiksir. Kemudian dilakukan kemoterapi menggunakan 
paslitaksel sebanyak 8 siklus tanpa radioterapi karena antrian jadwal terlalu panjang. Setelah 
kemoterapi pasien di re-evaluasi dan direncanakan operasi pengangkatan tumor. Pada 
operasi ditemukan obstruksi total esofagus dengan jaringan fibrotik sepanjang esofagus, 
namun tidak ditemukan masa tumor. Selanjutnya dilakukan partial esophagectomy 
dan anastomosis end to side menggunakan stapler CDH25. Operasi dilakukan dengan 
pendekatan thoracoabdominal. Pasien dipulangkan hari ke 12, kondisi baik dan sudah 
diet lunak. Direncanakan untuk evaluasi dengan pemeriksaan Carcinoembryonic Antigen 
(CEA) dan Positron Emission Tomography (PET) scan. Dapat disimpulkan, penatalaksanaan 
multimodalitas dengan kemoterapi dan pembedahan pada kasus adenokarsinoma esofagus 
1/3 distal memberikan hasil baik.
Keywords: esophageal adenocarcinoma – chemotherapy – paclitaxel – esophagectomy - 
gastrectomy
squamous cell carcinoma increased 3-fold in 
dark-skinned individuals, whereas the type 
of adenocarcinoma is more common in fair-
skinned individuals.2,4
Increased incidence of esophageal cancer 
is associated with risk factors for these 
cancers. Squamous cell carcinoma of the 
esophagus is associated with smoking and 
alcohol consumption, genetic factors such 
as tylosis, Plummer-Vinson syndrome, and 
environmental exposure such as ingestion 
of alkali and radiotherapy. Esophageal 
adenocarcinoma is often grown in the distal 
esophagus and is associated with esophagitis, 
Barrett’s esophagus, a metaplasia occurring in 
the distal gastroesophageal junction because 
of chronic irritation from gastroesophageal 
reflux disease (GERD). Obesity, whether 
related to their GERD or due to consumption 
of western-style diet is poor in vitamins, 
vegetables, fruit, fish, and poultry; is also a 
risk factor for esophageal adenocarcinoma.1,3,5
Esophageal cancer is often called the 
“silent cancer”. Most patients are diagnosed 
later because of the lack of symptoms in the 
early stages of the disease.6 Dysphagia and 
weight loss occurs in about 90% cases of 
esophageal cancer. Other symptoms include 
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odynophagia, hoarseness, cough, chest pain, 
melena, and residual symptoms (sequelae) of 
the spread of disease both locally advanced 
and distant spread. Approximately 75% of 
patients have lymph node involvement at the 
time of diagnosis.5,7
Esophagectomy is a primary management 
of early-stage esophageal cancer although 
its specific role in superficial cancer is still 
being debated ever since the development of 
endoscopic mucosal treatment. Nowadays, the 
scientific evidence is enough to recommend 
the multimodal treatment of locally advanced 
cancers using the combination of neoadjuvant 
chemotherapy or chemoradiotherapy (CRT) 
followed by surgery. Some clinicians just 
use definitive CRT to avoid mortality due to 
surgery.8
We report a case of adenocarcinoma of the 
esophagus treated with multimodal approach 
of chemotherapy followed by surgery.
CASE REPORT
A-52-years-old male was consulted 
to the Department of Digestive Surgery of 
Dr. Sardjito General Hospital as an already 
diagnosed case of esophageal tumor. He 
was consulted to the department at 9 March 
2015. The patient came with dysphagia as a 
chief complaint accompanied with nausea, 
vomiting, and weight loss. The onset of the 
symptoms started from December 2014, 
and gradually became more severe. At the 
beginning of the symptoms, he was capable 
of ingesting solid diet, but at the time he was 
consulted, he was only capable of ingesting 
liquid diet. During the illness, he lost his 
weight as much as 20 kg, which was from 
72 to 52 kg. Physical examination did not 
find any abnormality. Routine laboratory test 
found hemoglobin level was 9.7 mg/dL. 
The patient had been undergoing barium 
meal and endoscopic examination at prior 
hospital. Barium meal test revealed a suspected 
distal esophageal tumor with a malignant 
tendency (FIGURE 1). Endoscopy revealed 
an esophageal tumor at 35 cm depth. Biopsy 
on the mass was conducted during endoscopy 
procedure. Histopathology analysis result was 
moderately-differentiated adenocarcinoma of 
the esophagus.
FIGURE 1. Barium meal and endoscopic result
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The patient was diagnosed as distal 
esophageal tumor and elected to undergo 
gastrostomy and exploration laparotomy on 13 
March 2015. During exploration laparotomy, 
fixed, 7 x 6 x 5 cm3 esophagogastric junction 
mass was found. Nasogastric tube (NGT) 
could not pass through the tumor. Temporary 
gastrostomy was done and it was concluded 
that the esophageal tumor was unresectable 
and planned to undergo post-operative 
chemotherapy. He was consulted to Hemato-
oncology department to receive chemotherapy. 
Eight cycles of paclitaxel were administered 
and completed at 2 November 2015. Serial 
CT scan evaluation was done 3 times. First 
CT scan (29 May 2015) revealed narrowing 
of esophageal lumen, total obstruction on 
the level of 7th thoracic vertebrae, and no 
periesophageal infiltrating mass (FIGURE 2). 
Second CT scan (17 September 2015) showed 
intraluminal mass causing total obstruction 
below the level of 9th thoracic vertebrae, and 
no periseophageal infiltrating mass (FIGURE 
3). Third CT scan (9 November 2015) revealed 
distal esophageal mass with 1.4 x 1.2 x 3.4 
cm3 dimension, smaller than prior dimension 
(FIGURE 4). Esophagography (19 November 
2015) revealed stenosis of third distal of 
esophagus.
FIGURE 2. First CT scan (29 Mei 2015) showed narrowing of esophagus on the level of 7th thoracic ver-
tebra.
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FIGURE 3. Second CT scan (17 September 2015), CT coronal view showed intraluminal tumor of esophagus 
causing total obstruction on the level of 9th thoracic vertebra.
FIGURE 4.  Third CT scan (9 November 2015), CT coronal view showed decreasing of the intraluminal tumor 
dimension.
On 17 December 2015, he underwent 
laparotomy, thoracotomy, intraoperative 
endoscopy, resection and anastomosis of 
esophagus. Tumor mass was not found during 
the procedure, there was fibrotic tissue around 
esophagus and esophagogastric junction. 
Intraoperative endoscopy found stenosis 
of esophagus. Partial esophagectomy and 
gastrectomy was done, followed by gastro-
esophageal anastomosis using stapler CDH25. 
43
Histopaedianto et al., Assessing downgrading of esophageal adenocarcinoma 
after neoadjuvant chemotherapy: a case report
Patient clinical appearance following the 
procedure was better than before.
Post-operative anatomic pathology 
evaluation revealed adenocarcinoma with 
clean border. PET scan and tumor marker 
assay were planned as follow-up plan. 
Multimodality approach (chemotherapy and 
surgery) to management esophageal cancer 
gave a good outcome in this case.
DISCUSSION
Tumor or esophageal cancer has a high 
mortality rate and also known as “silent 
cancer” due to unspecific symptoms of an 
early stage of cancer and results in delayed 
diagnosis. Esophageal cancer is often to be 
found in 50-60 years old patient. Dysphagia 
and weight loss are the most reported 
symptoms in as much as 90% of the total case. 
The dysphagia is reported to be progressive, 
from difficult to ingest solid diet to liquid diet 
due to obstruction caused by cancer. Other 
symptoms are odynophagia, hoarseness, 
coughing, chest pain, and melena. Lymph node 
involvement is found in more than 75% cases. 
Physical examination in esophageal cancer 
shows no abnormality, except cervical and 
supraclavicular lymph nodes enlargement.5,7
Radiologic examination may support the 
esophageal cancer diagnosis. Barium contrast 
may show filling defect to differ obstruction 
related dysphagia or neurogenic related 
dysphagia. Esophagogastroduodenoscopy 
(EGD)  is the easiest way to observe dimension, 
circumferential and linear spread of the 
tumor, and may allow biopsy of the tumor. 
Endoscopic ultrasound (EUS) is a definitive 
method to establish tumor stage. According 
to TNM tumor staging of the American Joint 
Commission on Cancer (AJCC), tumor stage 
is determined based on invasion depth (T) 
and lymph node involvement (N). Computed 
tomography (CT) scan with contrast of chest 
and abdomen is not so helpful to examine far 
metastasis compared to fluorodeoxyglucose 
positron emission tomography (FDG-PET) 
scan.
According to Guidelines for Clinical 
and Pathologic Studies on carcinoma of the 
Esophagus on 2007, the esophagus is divided 
into 3: proximal, medial, and distal. Proximal 
part is also known as cervical esophagus (Ce), 
a short segment located on the median line 
goes along to posterior of the membranous 
trachea and anterior of the vertebral column. It 
ends on the same level as manubrium sternum. 
Thoracic part (Te) goes down on the anterior 
of the vertebral column and thoracic aorta 
through esophageal hiatus of the diaphragm. 
Thoracic part is divided into: the upper 
thoracic esophagus (Ut), the middle thoracic 
esophagus (Mt) and lower thoracic esophagus 
(Lt). The distal part of the esophagus is also 
called abdominal esophagus (Ae) which is 
the shortest part. It goes down from the level 
of esophageal hiatus to gastric cardia on the 
level of 11th or 12th thoracic vertebra. Overall, 
the esophagus is divided into 5 parts: Ce< Ut, 
Mt, Lt, and Ae which is related to esophageal 
cancer predilection (FIGURE 5).10
Histologically, the esophagus consists 
of 4 main layers: mucosal, submucosal, 
muscularis propia, and adventitia. There is no 
serous membrane in esophagus, which makes 
cancer cell is easier to spread. Stratified 
epithelia of esophageal mucosal layer consist 
of 3 compartments: basal layer, supra basal 
layer (intermedium or prickle layer), and 
superficial layer. Cells proliferate on basal 
layer and differentiate when migrating from 
suprabasal to superficial layer. Submucosal 
layer contains connective tissue, immune 
cells, neural cells, vascular tissue, and small 
mucoid gland. Muscularis propria of proximal 
esophagus consists of skeletal muscle which 
gradually change into smooth muscle on distal 
esophagus. Esophagus is covered by adventitia 
layer which is an external fibrous layer.6
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FIGURE 5. Five parts of the esophagus. O: esophageal 
orifice; S: upper margin of the sternum; B: 
tracheal bifurcation; D: diaphragm; EGJ: 
esophagogastric junction; H: esophageal hi-
atus. (Guidelines for Clinical and Pathologic 
Studies on Carcinoma of the Esophagus (9th 
edition), the Japanese Society for Esophageal 
Diseases) 
Histologically, esophageal cancer mainly 
divided into 2, squamous cell carcinoma and 
adenocarcinoma. Less than 1-2% is sarcoma or 
small cell carcinoma. Lymphoma, carcinoids, 
and melanoma is very rare.3 
Natural history of squamous cell 
carcinoma and adenocarcinoma of esophagus 
is different. Squamous cell carcinoma is started 
from inflammation of squamous epithelial 
and progressively change to dysplasia and in 
situ cancer. Adenocarcinoma tends to grow 
at distal esophagus from columnar-lined 
metaplastic epithelium which is also known as 
Barret’s esophagus. Gastro esophageal reflux 
disease (GERD) can damage esophageal 
surface. Approximately 75% of all esophageal 
adenocarcinoma are found at distal esophagus 
and squamous cell carcinoma is commonly 
found between middle part and third distal 
esophagus.1,3
Locally advanced esophageal cancer 
is esophageal cancer which is limited 
to esophageal or peri-esophageal tissue 
(>T1,≤T4a) and/or involves lymph nodes 
(N1-N3), without far metastasis (M0). 
According to AJCC/TNM staging, tumor 
which involves pleura, pericardium, or 
surrounding diaphragm, is resectable (T4a). 
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Otherwise, tumor which involves other 
structures such as aorta, trachea, vertebra, and 
etc., is unresectable.11
Locally advanced tumor is treated using 
resection surgery since esophagectomy with 
radical lymphadenectomy is the best choice 
to achieve local control.8 Surgical resection 
must involve radical, complete, RO, en bloc 
esophagectomy associated to an extended 
two-field lymphadenectomy.12
However, resection is associated with poor 
survival rate, metastasis risk, or locoregional 
recurrence post resection. On locoregional 
tumor, post resection 5-year survival rate is 
10-40%, with a risk of therapeutic failure due 
to far metastasis. Therefore, it is recommended 
to use multimodality management on locally 
advanced cancer which is neoadjuvant therapy 
or combined chemoradiotherapy (CRT) 
followed by resection. Some experts prefer 
definitive CRT to avoid surgical mortality 
risk. Radiotherapy only has 6% of 3-year 
survival rate. Prior study shows chemotherapy 
for locally advanced esophageal cancer has 
45%-75% of response rate. However, it has 
high relapse rate with poor long-term survival 
rate.8,13
Chemotherapy without radiotherapy 
before surgery has some advantages such 
as improvement in dysphagia symptom, 
better survival rate, disease-free survival 
before surgery, better control of local tumor 
or downstaging tumor, better resectability, 
and chance to eradicate micrometastasis by 
lowering cancer cell dissemination.8,13
Most commonly used chemotherapy 
regimen is cisplatin and 5-florouracil infusion. 
Other regimens are bleomycin, vinblastine, 
carboplatin, etoposide, and paclitaxel.11 
Although chemotherapy has high advantage, 
its use is limited by toxicity risk, especially 
in elderly. The more chemotherapy regimen 
combination we use, the more toxicity risk 
increase.14,15
Paclitaxel is a taxane anticancer drug. It is 
commonly used as chemotherapeutic agent in 
malignancy. It is a microtubule stabilizer that 
selectively inhibit cell on mitosis phase (M) 
without interfering synthesis phase (S). it may 
cause cytotoxicity, depends on administration 
time and concentration which is radiation 
sensitizer.16 It also has antiangiogenic activity, 
so that, it is a rational therapy to control cancer 
progressivity (FIGURE 6).17
FIGURE 6.  Pharmacologic mechanism of paclitaxel antiangiogenic activity. EPC: endothelial progenitor cells; 
TSP-1: thrombospondin-1; Ang-1: amgiopoetin-1; VEGF: vascular endothelial growth factor.17
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CONCLUSION
Multimodality management using 
chemotherapy and surgery gives a good 
outcome. Chemotherapy given prior to the 
surgery may decrease the dimension of 
the tumor, so that tumor resectability will 
increase. Post-operative anatomic pathology 
reveals adenocarcinoma with clean border. 
Post chemotherapy total stenosis is treated 
by partial esophagectomy and gastrectomy 
procedures. Esophago-gastric anastomosis 
using stapler CDH25 shows a good outcome.
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